{"log_id": 5782852194442391530, "direction": 0, "words_result_num": 26, "words_result": [{"probability": {"variance": 4.9e-05, "average": 0.998008, "min": 0.956455}, "location": {"width": 846, "top": 219, "height": 47, "left": 181}, "words": "受索拉非尼治疗的患者未报告高血压危象。高血压(收缩压>150mmHg,或舒张"}, {"probability": {"variance": 0.001707, "average": 0.988028, "min": 0.782015}, "location": {"width": 845, "top": 273, "height": 50, "left": 183}, "words": "压>100mmHg)的中位发生时间在开始阿昔替尼治疗后1个月内,并且在开始阿昔替尼"}, {"probability": {"variance": 0.000238, "average": 0.996059, "min": 0.90331}, "location": {"width": 847, "top": 331, "height": 47, "left": 182}, "words": "治疗后4天就观察到血压升高。可采用标准抗高血压药物治疗高血压。接受阿昔替尼治"}, {"probability": {"variance": 4.6e-05, "average": 0.99667, "min": 0.967014}, "location": {"width": 849, "top": 385, "height": 50, "left": 182}, "words": "疗的1359例患者(<1%)因高血压停止阿昔替尼治疗,接受索拉非尼治疗的患者无因"}, {"probability": {"variance": 0.000728, "average": 0.990567, "min": 0.891946}, "location": {"width": 339, "top": 453, "height": 34, "left": 184}, "words": "高血压停止治疗(见【不良反应】)"}, {"probability": {"variance": 5.2e-05, "average": 0.996589, "min": 0.969715}, "location": {"width": 800, "top": 494, "height": 48, "left": 230}, "words": "在开始阿昔替尼治疗前,应控制好血压。应监测患者高血压出现情况,同时按需给"}, {"probability": {"variance": 8e-06, "average": 0.998557, "min": 0.984636}, "location": {"width": 844, "top": 547, "height": 51, "left": 186}, "words": "予标准抗高血压药物治疗。如给予抗高血压药物治疗后仍存在持续性高血压,应降低阿"}, {"probability": {"variance": 3.7e-05, "average": 0.997262, "min": 0.964568}, "location": {"width": 844, "top": 602, "height": 49, "left": 187}, "words": "昔替尼剂量。如果同时给予抗高血压药物并降低阿昔替尼剂量仍出现严重且持续性高血"}, {"probability": {"variance": 1.1e-05, "average": 0.998389, "min": 0.983911}, "location": {"width": 845, "top": 659, "height": 46, "left": 189}, "words": "压,应停用阿昔替尼,一旦患者血压正常即重新开始给予较低剂量的阿昔替尼。如果出"}, {"probability": {"variance": 7e-06, "average": 0.998435, "min": 0.986377}, "location": {"width": 846, "top": 711, "height": 51, "left": 187}, "words": "现高血压危象证据,应考虑停药。如果中断阿昔替尼给药,应监测接受抗高血压药物治"}, {"probability": {"variance": 1e-05, "average": 0.99787, "min": 0.988971}, "location": {"width": 438, "top": 775, "height": 40, "left": 186}, "words": "疗的患者是否出现低血压(见【用法用量】)"}, {"probability": {"variance": 0.000173, "average": 0.994916, "min": 0.935302}, "location": {"width": 805, "top": 819, "height": 50, "left": 233}, "words": "如果怀疑存在可能与轻至重度高血压有关的可逆性后部脑白质病综合征(RPLS)"}, {"probability": {"variance": 0, "average": 0.964521, "min": 0.964521}, "location": {"width": 38, "top": 853, "height": 20, "left": 829}, "words": "T"}, {"probability": {"variance": 3e-06, "average": 0.998435, "min": 0.99349}, "location": {"width": 455, "top": 884, "height": 39, "left": 198}, "words": "(见下),则应考虑进行诊断性脑部磁共振成像"}, {"probability": {"variance": 2.1e-05, "average": 0.995589, "min": 0.985071}, "location": {"width": 186, "top": 945, "height": 33, "left": 190}, "words": "动脉血栓栓塞事件"}, {"probability": {"variance": 0, "average": 0.724279, "min": 0.724279}, "location": {"width": 111, "top": 933, "height": 50, "left": 880}, "words": "不"}, {"probability": {"variance": 8.5e-05, "average": 0.997047, "min": 0.946541}, "location": {"width": 801, "top": 984, "height": 48, "left": 237}, "words": "在临床试验中,已报告包括死亡在内的动脉血栓栓塞事件。在接受阿昔替尼治疗的"}, {"probability": {"variance": 0.00114, "average": 0.989255, "min": 0.808503}, "location": {"width": 845, "top": 1038, "height": 51, "left": 192}, "words": "RCC患者对照临床试验中,接受阿昔替尼治疗的4359例患者(1%)和接受索拉非尼"}, {"probability": {"variance": 0.003314, "average": 0.986189, "min": 0.629157}, "location": {"width": 845, "top": 1094, "height": 48, "left": 194}, "words": "治疗的4/355例患者(1%)报告3/4级动脉血栓栓塞事件。在接受阿昔替尼治疗的359"}, {"probability": {"variance": 5.6e-05, "average": 0.996211, "min": 0.969667}, "location": {"width": 844, "top": 1147, "height": 51, "left": 196}, "words": "例患者中,有1例患者(<1%)报告致死性脑血管意外。在接受索拉非尼治疗的患者中"}, {"probability": {"variance": 2.9e-05, "average": 0.996895, "min": 0.978545}, "location": {"width": 436, "top": 1212, "height": 39, "left": 195}, "words": "未报告致死性脑血管意外(见【不良反应】)"}, {"probability": {"variance": 0.005638, "average": 0.980908, "min": 0.529931}, "location": {"width": 802, "top": 1258, "height": 49, "left": 240}, "words": "在阿昔替尼临床试验中,有17/715例患者(2%)报告动脉血栓栓塞事件(包括一"}, {"probability": {"variance": 3e-06, "average": 0.998826, "min": 0.992924}, "location": {"width": 846, "top": 1314, "height": 50, "left": 196}, "words": "过性脑缺血发作、脑血管意外、心肌梗死、视网膜动脉闭塞),有2例死亡继发于脑血"}, {"probability": {"variance": 2.2e-05, "average": 0.993307, "min": 0.989418}, "location": {"width": 68, "top": 1390, "height": 27, "left": 199}, "words": "管意外"}, {"probability": {"variance": 5.2e-05, "average": 0.992025, "min": 0.98064}, "location": {"width": 128, "top": 1583, "height": 24, "left": 564}, "words": "第8页,共27页"}, {"probability": {"variance": 0.008414, "average": 0.946859, "min": 0.730738}, "location": {"width": 94, "top": 1616, "height": 19, "left": 259}, "words": "No:20150429"}], "language": 3}